Full-Time

Field Support Representative

Diagnostics

IDEXX

IDEXX

5,001-10,000 employees

Veterinary diagnostics, lab services, software

Compensation Overview

$30 - $35/hr

+ Annual cash bonus + 5% 401(k) match

Company Does Not Provide H1B Sponsorship

Houston, TX, USA + 1 more

More locations: Corpus Christi, TX, USA

Hybrid

Residency in the Houston South or Corpus Christi areas is required; self-relocation is required if assigned outside the territory.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Computer Networking
CRM

Get referred to IDEXX

See people who can refer or advise you

Requirements
  • Three or more years of experience working in a veterinary practice or similar work experience.
  • Familiarity with IDEXX products.
  • A valid driver's license and acceptable driving record are required.
  • Residency in the Houston South or Corpus Christi areas and willingness to travel within the assigned territory and occasionally outside it as needed.
  • Ability to build and maintain relationships and gain confidence and trust from others.
  • Strong communication and ability to collaborate with customers, management, and peers.
  • Planning and prioritization skills to make quality, timely decisions.
  • Effective listening skills to discover customer needs and adapt approach and demeanor to different situations.
  • Comfort learning and using technology such as computers, tablets, and smartphones; computer networking experience is a plus.
  • Ability to perform the physical aspects of the role, including reaching, handling, manipulating objects, climbing, balancing, bending, stooping, kneeling, crouching, and lifting, moving, and carrying up to 60 pounds.
  • Specific vision abilities including close vision, color vision, depth perception, and the ability to adjust focus.
  • Hearing acuity sufficient to communicate effectively with customers and employees by telephone and in person.
  • Ability to communicate effectively in English with customers and team members.
  • Ability to travel and work within the assigned area, drive a car for extended periods, and work with or have contact with animals.
Responsibilities
  • Work collaboratively with an internal team to develop strategies and maintain customer accounts through education and customer-centric solutions.
  • Visit customers daily, adjust the schedule as needed to support customer events, and occasionally accommodate visits to emergency practices.
  • Install IDEXX Analyzers and train clinic staff in their effective use, including ProCyte, Catalyst One, SediVue, and InVue.
  • Support critical customer visits by providing onsite technical troubleshooting when issues arise.
  • Use programs to plan and strategize customer visits and serve as an IDEXX representative and trusted customer partner.
  • Manage the schedule based on customers' unique attributes and needs while focusing on professional development and growth.
  • Travel up to 75% of the time, including five or more days of car travel per week and six to eight or more overnight stays per month; weekend hours and weekday overtime may be required.
  • Work from a home-based office when not traveling.
Desired Qualifications
  • Computer networking experience.

IDEXX Laboratories provides veterinary diagnostics, laboratory services, and practice management software for companion animals, livestock, and related markets. Its offerings include in-clinic diagnostic instruments and tests, centralized reference labs, and software subscriptions that streamline testing, data management, and workflows. The company differentiates itself with a vertically integrated, end-to-end ecosystem that combines clinical diagnostics, laboratory services, and software. Its goal is to improve animal health outcomes and veterinary practice efficiency through accurate testing and data-driven decision making.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Westbrook, Maine

Founded

1983

Get referred to IDEXX

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $1.217 billion; EPS rose 18%, and guidance increased.
  • Catalyst proBNP launches October 2026 in North America, opening cardiac testing revenue.
  • Cancer Dx mast cell testing and inVue FNA broaden menus across 10,000-plus clinics.

What critics are saying

  • U.S. same-store clinical visits fell 1.3% in Q2 2026; wellness visits stayed weak.
  • Reuters on February 2, 2026 flagged roughly 2% U.S. visit declines and lower pricing.
  • If wellness traffic stays down through 2027, IDEXX's consumables annuity weakens materially.

What makes IDEXX unique

  • Catalyst reached 79,800 installed units; consumables create recurring veterinary revenue.
  • inVue Dx surpassed 9,100 installations by August 2026, expanding slide-free in-clinic workflows.
  • Cornerstone software and reference labs lock clinics into IDEXX's diagnostic ecosystem.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Mental Health Support

Pet Insurance

Employee Stock Purchase Plan

Volunteer Paid Days Off

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
Associated Press
Aug 11th, 2026
IDEXX launches first dual-species cardiac test on 80,000-unit Catalyst platform, targets $4B market

IDEXX Laboratories has launched the Catalyst proBNP Test, the first dual-species, in-clinic test for NT-proBNP biomarker to evaluate heart disease in cats and dogs. The test runs on IDEXX's Catalyst platform, which has nearly 80,000 analyzers installed globally. The test delivers results during patient visits, reducing reliance on referrals and expanding access to cardiac assessment where specialist services are limited. It supports screening, diagnosis, and monitoring of heart disease, which affects approximately one in six cats and one in 10 dogs. IDEXX estimates the global cardiac testing opportunity at approximately $4 billion. The test will be available in North America from October 2026, with international rollout to follow.

The Montreal Gazette
Aug 11th, 2026
IDEXX expands Catalyst platform into cardiac disease with first and only dual-species point-of-care NT-proBNP test.

IDEXX expands Catalyst platform into cardiac disease with first and only dual-species point-of-care NT-proBNP test. New test brings quantitative cardiac assessment for cats and dogs into everyday workflows WESTBROOK, Maine - IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst(TM) proBNP Test, the first and only dual-species, in-clinic test for NT-proBNP, expanding cardiac capabilities across its connected point-of-care and reference...

Mainebiz
Aug 4th, 2026
IDEXX Q2 earnings jump 18%, beating expectations.

IDEXX Q2 earnings jump 18%, beating expectations. August 4, 2026 IDEXX Laboratories Inc. (Nasdaq: IDEXX) posted second-quarter results that exceeded Wall Street expectations and again raised its full-year financial outlook. The Westbrook-based maker of veterinary diagnostics and software posted diluted earnings per share of $4.27, representing an increase of 18% as reported and 15% on a comparable basis from a year ago. The figure exceeds that $3.95 per share consensus estimate of analysts polled by Zacks Investment Research. It also includes 14 cents a share in tax benefits from share-based compensation and a boost of 6 cents a share from year-over-year currency changes. In each of the past four quarters, the company has surpassed consensus earnings estimates. Q2 revenue was $1.22 billion, an increase of 10% as reported and 9% organic, driven by growth in the company's Companion Animal Group division. The figure is 1.28% above the Zacks consensus estimate. Mike Erickson, who recently took the helm as IDEXX's president and CEO, said the results reflect continued innovation across various diagnostic platforms. "This is the kind of durable, compounding growth we're building for the long term, helping veterinarians see more and do more for their patients while creating lasting value for our shareholders," he added. As of Monday's close on Wall Street, IDEXX shares have a market value of around $44.8 billion. That's 17% lower than a year ago. Updated outlook. In its updated outlook for the full year, IDEXX is projecting earnings per share to be in the range of $14.69 to $14.94. That's 14 cents higher at the midpoint level than previously. IDEXX also expects full-year revenue guidance to be in the range of $4.7 billion to $4.75 billion, or reported growth of 9.1% to 10.3%. That represents an increase of $5 million at midpoint, despite a stronger U.S. dollar resulting in a $15 million net reduction to projected revenues. IDEXX increased its full-year reported operating margin outlook to 32.3% to 32.5%, bringing the projected full-year operating profit margin expansion to 70 to 90 basis points as reported and on a comparable basis. IDEXX said the updated outlook benefits from strong second-quarter operating performance along with advancing strategic investment priorities. The company also projects a higher full-year reported operating margin, citing strong second-quarter operating performance and a focus on strategic investments. - Digital Partners -

Yahoo Finance
Aug 4th, 2026
IDEXX Laboratories raises 2026 EPS outlook to $14.69-$14.94 after 18% Q2 growth

IDEXX Laboratories reported second quarter 2026 revenue of $1,217 million, up 10% as reported and 9% organically. Companion Animal Group Diagnostics recurring revenue grew 11% as reported and 10% organically, driven by volume and expanding diagnostics utilization. The company's IDEXX inVue Dx installed base exceeded 9,000 instruments, with over 1,600 placements during the quarter. Earnings per share reached $4.27, up 18% as reported and 15% on a comparable basis. Operating margin increased 140 basis points as reported. IDEXX narrowed its 2026 revenue guidance to $4,700-$4,745 million and raised its EPS outlook to $14.69-$14.94, representing a $0.14 increase at midpoint. The company expects organic revenue growth of 8.5%-9.7% for the full year.

ElleVet Sciences
Jul 22nd, 2026
ElleVet Sciences expands leadership team with two key additions.

ElleVet Sciences expands leadership team with two key additions. * Posted On - * Published - Jul 22, 2026 ElleVet Sciences expands its leadership team, appointing Robyn Cash and Ryan Dean to lead Human Resources and Finance SOUTH PORTLAND, MAINE (July 22, 2026) - ElleVet Sciences, the science-backed leader in CBD + CBDA products for pets, is proud to announce two key additions to the organization's leadership team with the promotion of Robyn Cash to Director, Human Resources and the hiring of Ryan Dean as Senior Director, Finance. "ElleVet continues to invest significantly in clinical research, analytical capabilities, and science-driven product development to provide groundbreaking, highly effective supplements to veterinarians and pet parents. Robyn and Ryan are valuable additions to the leadership team - attracting and retaining top talent and optimizing strong financial competencies is critical for us as we continue to grow and scale," said Christian Kjaer, Executive Chair and cofounder of ElleVet Sciences. Robyn Cash joined ElleVet in 2023 as Senior Recruiter, where she helped develop ElleVet's growing team. "I am proud to be part of ElleVet Sciences, a company driven by science, backed by a successful history, and positioned for an exciting future," said Cash, who now leads the Human Resources function. "This promotion provides an opportunity for me to contribute even more to ElleVet's strategic direction while continuing to support the growth and development of the exceptional talent we have across the organization." Ryan Dean, formerly of IDEXX, joined ElleVet in July as Senior Director of Finance. Dean shared, "I am looking forward to leading the finance team at ElleVet and helping shape the next chapter of the organization by building on the strong foundation in place. I am grateful to work for a science-focused, mission-driven organization and am energized by the fact that our work helps pets live better lives." Over the years, ElleVet Sciences has invested in more than 40 clinical studies and R&D initiatives and published more than 23 peer-reviewed studies demonstrating the safety and efficacy of its products, reflecting the company's commitment to developing the best possible products for pets. As the company continues to grow, ElleVet is strengthening its organization to accelerate innovation, advance its mission, and meet increasing customer demand. About ElleVet Sciences: ElleVet Sciences is a leading science-driven animal health company headquartered in South Portland, Maine. As the first organization to conduct successful clinical trials on the safety and efficacy of CBD + CBDA for pets, ElleVet continues to lead the field through research and innovation in collaboration with top veterinary professionals and institutions. The company has pioneered and patented safe, effective products for dogs, cats, and horses, offering support for mobility, stress, skin health, and brain function. Carried by thousands of veterinary clinics across the US, ElleVet is committed to improving the lives of companion animals, with both heart and science at the core of its mission.